No abstract

EGb 761, 240 mg once-daily, was found significantly superior to placebo in the treatment of patients with dementia with neuropsychiatric symptoms.

Introduction: A 24-week randomised controlled trial was conducted to assess the efficacy of a 240?mg once-daily preparation of Ginkgo biloba extract EGb 761? in 404 outpatients?50 years diagnosed with mild to moderate dementia (SKT 9?23), Alzheimer?s disease (AD) or vascular dementia (VaD), with neuropsychiatric features (NPI total score?5). Methods: Separate analyses were performed for diagnostic subgroups (probable or possible AD; VaD). Results: 333 patients were diagnosed with AD and 71 with VaD. EGb 761? treatment was superior to placebo with respect to the SKT total score (drug-placebo differences: 1.7 for AD, p<0.001, and 1.4 for VaD, p<0.05) and the NPI total score (drug-placebo differences: 3.1 for AD, p<0.001 and 3.2 for VaD, p<0.05). Significant drug-placebo differences were found for most secondary outcome variables with no major differences between AD and VaD subgroups. Rates of adverse events in EGb 761? and placebo groups were essentially similar. Conclusion: EGb 761? improved cognitive functioning, neuropsychiatric symptoms and functional abilities in both types of dementia.

No abstract

The results demonstrate a statistically significant and clinically relevant superiority of add-on therapy with EPs 7630 over placebo and a good long-term tolerability in the treatment of moderate to severe COPD. EPs 7630 prolonged time to exacerbations and reduced exacerbation frequency and antibiotic use. Trial Registration No.: ISRCTN01681733.